Stimulating Full-Length SMN2 Expression by Delivering Bifunctional RNAs via a Viral Vector
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder that is the leading genetic cause of infant mortality. SMA is caused by the loss of survival motor neuron-1 (SMN1). In humans, a nearly identical copy gene is present, called SMN2. SMN2 is retained in all SMA patients and encodes an identical protein compared to SMN1. However, a single silent nucleotide difference in SMN2 exon 7 results in the production of a spliced isoform (called SMNDelta7) that encodes a nonfunctional protein. The presence of SMN2 represents a unique therapeutic target since SMN2 has the capacity to encode a fully functional protein. Here we describe an in vivo delivery system for short bifunctional RNAs that modulate SMN2 splicing. Bifunctional RNAs derive their name from the presence of two domains: an antisense RNA sequence specific to a target RNA and an untethered RNA segment that serves as a binding platform for splicing factors. Plasmid-based and recombinant adeno-associated virus vectors were developed that expressed bifunctional RNAs that stimulated SMN2 exon 7 inclusion and full-length SMN protein in patient fibroblasts. These experiments provide a mechanism to modulate splicing from a variety of genetic contexts and demonstrate directly a novel therapeutic approach for SMA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381 · cited 1×
“Virus production. Plasmid DNA from each bifunctional clone was triple transfected with the previously described pXX6 (encodes VA, E2A, and E4) and pAD8 (encodes AAV2 Rep and Cap proteins) helper plasmids into HEK 293 XDC cells [36, 37 ] using 7.5 mM polyethyleneimine.”
MethodInfluentialAlternative splicing in disease and therapy
Garcia-Blanco, M. A., Baraniak, A. P., & Lasda, E. L. (2004) · Nature Biotechnology · doi:10.1038/nbt964 · Cited by 527
Brichta, L. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg256 · Cited by 382
Cited by
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456
The SR protein family of splicing factors: master regulators of gene expression
Long, J. C., & Caceres, J. F. (2009) · Biochemical Journal · doi:10.1042/bj20081501 · Cited by 1,137
Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon
Hua, Y., Vickers, T. A., Baker, B. F., Bennett, C. F., & Krainer, A. R. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050073 · Cited by 340
Systemic Delivery of scAAV9 Expressing SMN Prolongs Survival in a Model of Spinal Muscular Atrophy
Valori, C. F., Ning, K., Wyles, M., Mead, R. J., Grierson, A. J., Shaw, P. J., & Azzouz, M. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000830 · Cited by 285
Spinal muscular atrophy: mechanisms and therapeutic strategies
Lorson, C. L., Rindt, H., & Shababi, M. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq147 · Cited by 209
Metadata
- Authors
- Baughan, T., Shababi, M., Coady, T. H., Dickson, A. M., Tullis, G. E., & Lorson, C. L.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2006-07
- Volume
- 14
- Issue
- 1
- Pages
- 54-62
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W1977592362
- Cited by
- 73
- References
- 3
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Stimulating Full-Length SMN2 Expression by Delivering Bifunctional RNAs via a Viral Vector. https://app.cochat.ai/papers/10.1016/j.ymthe.2006.01.012
- The paper
- Baughan, T., Shababi, M., Coady, T. H., Dickson, A. M., Tullis, G. E., & Lorson, C. L. (2006). Stimulating Full-Length SMN2 Expression by Delivering Bifunctional RNAs via a Viral Vector. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2006.01.012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.